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Abstract
Cardiogenic shock (CS) is an end-organ hypoperfusion associated with heart failure. Any 
reason impairing acute left ventricular (LV) or right ventricular (RV) function may cause 
CS. The only way to avoid CS is to provide early reperfusion in myocardial infarction 
(MI) patients. CS is characterized by permanent or transient rearrangement of the entire 
circulatory system. According to the current IABP-SHOCK II trial, 74% of the patients 
with CSMI are treated with norepinephrine, 53% of them with dobutamine, 26% of them 
with epinephrine, 4% of them with levosimendan, and 4% of them with dopamine. 
Percutaneous circulatory support devices such as intra-aortic balloon pump (IABP), 
LV assist device (LVAD), or extracorporeal life support (ECLS) create treatment options 
for selected patients such as CS, cardiopulmonary resuscitation, or high-risk pPCI and 
CABG. Extracorporeal Life Support Organization (ELSO, 2017) evaluated that the use of 
ECLS/VA-ECMO should be considered when the mortality risk exceeds 50% despite opti-
mal conventional treatment in case of acute severe heart or pulmonary failure, whereas 
it should be assessed as a primary indication when it exceeds 80%. Early and effective 
revascularization is the best treatment option for CS. Thus, the organizations on the 
national and global basis will play the most effective role for the short- and long-term 
survival of patients.
Keywords: cardiogenic shock, multiple organ failure, inotropes, left ventricular assist 
devices
1. Introduction
Cardiogenic shock (CS) is one of the most important issues dealt by cardiologists today and 
still needs solutions. Prevention, accurate diagnosis, urgent intervention, effective support 
for heart failure, and multi-organ failure (MOF) are what this endeavor involves [1]. More 
than 90% of patients arriving at the hospital with acute myocardial infarction (MI) are likely 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
to survive [2]. CS occurs in approximately 5–8% of inpatients with ST-elevation myocardial 
infarctions (STEMI) and has a mortality rate of more than 30% [1]. CS is caused by end-organ 
hypoperfusion due to impaired cardiac pump function. Although CS-related mortality has 
declined significantly over the past decade, it continues to remain high, especially in cases of 
its coexistence with ischemic heart disease. Acute coronary syndrome (ACS) is still the most 
common cause of CS despite significant advances that have been made in its diagnosis and 
treatment. The most successful form of treatment is primary percutaneous coronary interven-
tion (pPCI), which is carried out as rapidly as possible [3]. The recent research has suggested 
that the peripheral vasculature and neurohormonal and cytokine systems also play a role in 
the pathogenesis and persistence of CS.
In cases where CS complicates MI (CSMI), only one in two patients survives after 1 year [4, 5]. 
In a large study including 5782 patients, CSMI had developed in 2.5% of the patients with 
STEMI before admission to hospital, in 4.3% of them on the first day of hospitalization, and 
in 2.3% of them afterward [6]. For non-STEMI (NSTEMI) patients, these ratios were 1.2% for 
each condition [6]. Mortality rates were 45.7% before the hospitalization, 32.8% in the early 
period, and 54.1% in the late period [7]. Of 1422 CSMI patients, in the SHOCK Trial Registry, 
a shock is developed following left ventricular failure in 78.5% of them, acute mitral insuffi-
ciency in 6.9% of them, acute ventricular septal defect in 3.9% of them, right ventricular failure 
in 2.8% of them, cardiac tamponade in 1.4% of them, and other reasons in 6.7% of them [8].
2. Diagnosis and causes
2.1. Definition
CS is an end-organ hypoperfusion associated with heart failure. In terms of the hemodynamic 
parameters used in the definition of CS, it is characterized by a systolic blood pressure of 
80–90 mmHg, a cardiac index below 1.8 L min−1 m−2 without support and below 2.0–2.2 L min−1 m−2 
with support, a mean arterial baseline under 30 mmHg, and a pulmonary capillary wedge 
pressure of 15 or >18 mmHg [9].
2.2. Diagnosis
However, it is not necessary to measure these parameters in order to make the diagnosis of 
CS. Hypotension is not observed at the start in one-fourth of the patients diagnosed with 
CSMI. In this case, the diagnosis is made according to the clinical findings of organ hypo-
perfusion including extremity coldness, oliguria, and changes in mental condition such as 
agitation. It is imperative to distinguish MI-related complications, from primarily mechanical 
complications. The main complications are ventricular septal defect, free wall, and papillary 
muscle rupture developing after MI. Usually, if it is the first MI event and there is no ante-
rior involvement, it should be considered that mechanical complications may have occurred. 
First of all, diagnosing CSMI should begin by quickly obtaining a 12-lead ECG (STEMI) and 
examining the clinical findings with respect to CS. In rare instances, the diagnosis of NSTEMI 
can be made based on the clinical criteria and troponin levels. Performing a rapid echocar-
diography (ECHO) before PCI may discount these complications, and, at the same time, the 
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detection of any pre-angiographic valve disease may alter the revascularization approach. 
Bleeding, infection, and/or intestinal ischemia may also cause shock in cases of MI. In these 
situations, patient survivability depends on being skeptical and makes a rapid diagnosis 
along with correct intervention.
2.3. Causes
Anything that impairs acute left ventricular (LV) or right ventricular (RV) function may cause 
CS. In cases of acute myopericarditis, tako-tsubo, and hypertrophic cardiomyopathy, shock 
may present with ST elevation in which cardiac markers are released without coronary artery 
disease. Stress-induced cardiomyopathy, also known as apical ballooning or tako-tsubo car-
diomyopathy, is a syndrome of acute LV dysfunction after emotional or respiratory distress 
leading to CS in 4.2% of cases [10]. Chordal rupture caused by degenerative diseases and 
trauma and acute valvular insufficiency caused by endocarditis may also cause CS. Severe 
aortic insufficiency (regurgitation) or coronary involvement developing as a result of aortic 
dissection may cause CS. Stress occurring in cases of severe aortic or mitral stenosis can cause 
shock. Cardiac tamponade and massive pulmonary embolism may cause shock without pul-
monary congestion.
2.4. Risk identification
The only way to avoid CS is to provide early reperfusion in MI patients. In a randomized 
trial, CS occurred less frequently compared to PCI in STEMI patients treated with thrombo-
lytic therapy within the first 2 hours of symptom onset before hospitalization (1.3 vs. 5.3%, 
p = 0.032) [11]. Low blood pressure and accelerated heart rhythm in patients admitted to hos-
pital suggest shock. Advanced age, anterior MI, hypertension, diabetes mellitus, multivessel 
coronary artery disease, previous MI or angina, or being diagnosed with heart failure, STEMI, 
and left bundle branch block are risk factors for the development of CS [12].
3. Physiopathology
CS is characterized by permanent or transient rearrangement of the entire circulatory system. 
The primary cause of many CS instances is the failure of LV pump function, but other compo-
nents of the circulatory system, inadequate compensation, or additional defects can also con-
tribute to this condition. The fact that surviving patients demonstrate improved functionality 
explains that all or some of these changes are completely reversible.
3.1. Left ventricle
The degree of LV myocardial dysfunction usually initiates CS. In most cases, it is not severe. 
Left ventricular dysfunction reflects newly onset irreversible damage, reversible ischemia, 
and previous infarct-related injury in CS. Myocardial injury causes systolic and diastolic dys-
function. Low blood pressure helps by reducing afterload due to the unique position of the 
heart even though it causes damage at the same time by impairing the coronary blood flow. It 




area. Reduction in coronary perfusion causes deterioration in perfusion of the heart and other 
vital organs by causing a decline in cardiac output (CO). Metabolic impairments occur inside 
and outside of the infarct region. Hypoperfusion leads to catecholamine discharge, resulting 
in an increase in contractility and peripheral blood flow, while, at the same time, increased 
contractility causes increased oxygen demand on the part of the myocardium, as well as 
arrhythmia and myocardial toxic effects [13]. Systemic inflammation may play a limiting 
role in peripheral vascular compensatory response or may only be considered as an epiphe-
nomenon. Revascularization makes the ischemia disappear, but increased CO or LV ejection 
fraction (LVEF) could not be shown as a benefit of revascularization. Revascularization sig-
nificantly increases the quality of life as well as survival rates [14, 15].
Vasoconstrictors and inotropic agents are able to correct CO and peripheral circulation tem-
porarily, but they do not break this vicious cycle. Although rapid intra-aortic balloon pump 
(IABP) application improves ischemia transiently and supports the circulation, it is not the 
final solution. Correcting coronary occlusion through surgery or PCI will break the vicious 
cycle and increase survival.
In the light of CS’s complex pathophysiology, the cause of shock in many cases is a severe 
impairment in contractility and moderate disruption in the LVEF [16]. LVEF was found 
approximately 30% in the SHOCK trial [17]. In terms of LVEF value, the SHOCK trial obscures 
many post-MI studies in which LVEF decreases with or without heart failure. The LVEF in 
this study generally does not indicate that the magnitude of myocardial damage causes CS, 
although it is measured in patients with inotropic and/or IABP support. LVEF is the same 
in the acute phase of CS, and 2 weeks later, its functional status is different [18]. Even when 
there are conditions in which there is no serious mitral regurgitation and the LV is preserved, 
CS still develops in some patients [19]. LVEF is a prognostic indicator in patients who end up 
with shock. The size of the LV is small or normal in about half of patients with CS [19]. LV 
dilatation is an adaptive mechanism of failure in order to provide stroke volume in the early 
phase. LV dilatation in the chronic phase may be maladaptive. The LV end-diastolic volume 
was shown to increase slightly to 15 mL as a result of the serially performed echo within the 
first 2 weeks in the survivors of CS [18].
3.2. Right ventricle
The RV may cause or contribute to CS. Shock based on the dominance of the RV occurs in 5% 
of CSMI cases. RV insufficiency may limit CO, ventricular interdependence, or both of them 
by decreasing LV filling. The treatment of patients with RV dysfunction and shock focuses not 
on reducing CO and on maintaining adequate right heart filling pressure in order to provide 
adequate LV preload in the conventional sense. However, in these patients, there is usually a 
very high RV end-diastolic pressure above 20 mmHg due to RV dysfunction [20]. The increase 
in RV end-diastolic pressure shifts the interventricular septum to the left via mechanical pres-
sure, thus impairing the functions by reducing the filling [21]. This means that aggressive fluid 
resuscitation in RV dysfunction is actually the incorrect method. Inotropic therapy should be 
initiated if it persists despite optimization of RV end-diastolic pressure in the CS secondary to 
the RV. Maintaining RV end-diastolic pressures between 10 and 15 mmHg provides the best 
CO [22]. Inhaled nitric oxide (NO) may be useful in reducing pulmonary vascular resistance 
and promoting forward flow. Shock secondary to RV dysfunction has a mortality rate as high 
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as that of shock secondary to LV dysfunction. The benefit of revascularization was similar in 
the SHOCK registry for patients with primarily RV dysfunction and those with primarily LV 
dysfunction [20].
Hypoperfusion of the extremities and vital organs is a sign of CS. MI-induced CO reduction 
and persistence of ischemia both result in the release of catecholamines leading to constric-
tion of the peripheral arteries and, thus, affecting the maintenance of perfusion to the vital 
organs. Attempts to improve peripheral and coronary circulation at the expense of elevation 
in afterload by increasing the levels of vasopressin and angiotensin II at the beginning of MI 
and shock will subsequently lead to impairment in myocardial functions. The continuation of 
neurohormonal cascade activation will also increase acute pulmonary edema while attempt-
ing to improve perfusion by causing water and salt retention. The reflex increase of systemic 
vascular resistance (SVR) mechanism is not fully effective. The SHOCK trial showed that SVR 
was at mean levels during CS despite vasopressor treatment and that in some cases it was 
even as low as in a septic shock [23]. Sepsis was suspected in 18% of the cohort of the SHOCK 
trial, 74% of which developed positive bacterial cultures. SVR was lower in these patients, 
and low SVR preceded the clinical diagnosis of infection and culture positivity by days [23].
Findings and observations of MI may cause systemic inflammatory response syndrome (SIRS). 
Inappropriate vasodilation as part of SIRS results in impaired perfusion of the intestinal tract 
leading to the transmigration of bacteria and sepsis. As the duration of shock increases, so the 
possibility of SIRS increases [24].
Sometimes, the medications given can contribute to the development of CS. Numerous medi-
cations such as beta-blockers, angiotensin-converting enzyme inhibitors, and morphine were 
associated with the development of shock. The early use of these treatments contributes in a 
small way to increase the risk of CS. However, given the large patient population receiving 
this treatment, the number of incidents it causes significant [25, 26]. The timing of CS (early 
after medication initiation) in the placebo-controlled, randomized trials of β-blockage and 
angiotensin-converting enzyme inhibition combined with their mechanisms of action indi-
cates that they may contribute to the development of CS in those at high risk.
Diuretics may also contribute to the development of post-MI shock [14]. The earliest effect 
of ischemia is usually a reduction in LV compliance. MI may cause pulmonary edema before 
a drop occurs in CO. The redistribution of intravascular volume to the lungs causes a clear 
decline in the volume of circulating plasma before heart failure. High-dose diuretics adminis-
tered subsequently further reduce plasma volume. Low diuretic dose coupled with low-dose 
nitrates and positional measures to decrease preload (e.g., seated position with legs down) 
should be attempted in patients with MI and pulmonary edema to avoid precipitating shock. 
Excessive volume loading in patients with RV infarction may also cause or contribute to shock.
4. Treatment
4.1. Supportive treatment
For MI, giving aspirin and heparin routinely along with antithrombotic treatment is recom-




depending on the results of coronary angiography, clopidogrel therapy may be delayed to the 
period after emergency angiography. There are indications of clopidogrel in all patients who 
are to undergo PCI, and this will be useful in MI patients with shock depending on the infor-
mation obtained from non-shock MI patients. The use of vasodilators including negative ino-
tropes and nitroglycerin should be avoided. The arterial oxygen and pH levels should be kept 
within normal limits in order to minimize the ischemia. Intensive insulin therapy improves 
survival in critically ill patients with hyperglycemia and is a recommended course of action in 
complicated MI [27]. An easy indication should be established in order to initiate mechanical 
ventilation with mask or endotracheal intubation. Positive end-expiratory pressure reduces 
preload and afterload. Mechanical ventilation also reduces respiratory workload.
4.2. Hemodynamic management
Pulmonary artery (PA) (Swan-Ganz) catheterization is frequently recommended in order to 
confirm the diagnosis of CS. There has been a decline in the use of PA catheters following the 
controversy caused by a prospective observational study suggesting that PA catheters are 
associated with poor outcome [28]. The use of PA catheters in severely hypotensive patients 
with MI can be performed according to patient [27]. At present, many clinics do not prefer PA 
catheter for CS treatment anymore. Clinical assessment with ECHO is a reasonable alterna-
tive: Both PA systolic pressure and wedge pressure can be accurately estimated with Doppler 
ECHO. In particular, finding a short mitral deceleration time (≤140 ms) is highly predictive of 
pulmonary capillary wedge pressure ≥20 mmHg in CS [19].
4.3. Pharmacological treatment
According to the German-Austrian CSMI guideline, dobutamine should be preferred as an 
inotrope option, norepinephrine as a vasopressor option, and levosimendan over phospho-
diesterase III inhibitors in case of refractiveness to catecholamines [29]. In the current IABP-
SHOCK II trial, 74% of the patients with CSMI were treated with norepinephrine, 53% of them 
with dobutamine, 26% of them with epinephrine, 4% of them with levosimendan, and 4% of 
them with dopamine [5, 30].
Since the survival outcomes of high-dose vasopressor use are poor, pharmacological support 
including these agents should be kept to a minimum [31]. This indicates the underlying seri-
ous hemodynamic derangement and toxic effects. Inotropic agents play a central role in the 
treatment because the event initiating the shock is contractile dysfunction. Unfortunately, ino-
tropes increase myocardial ATP consumption, so when the heart fails and supply is already 
limited, short-term hemodynamic healing occurs at the expense of increased oxygen demand. 
In order to provide coronary and systemic perfusion, the use of inotropic and vasopressor 
agents is required until IABP is placed or shock recovers. Norepinephrine is recommended in 
cardiac hypotension due to its high potential [27]. Both dopamine and norepinephrine have 
inotropic properties, but dobutamine is often required in addition.
4.3.1. Norepinephrine
The mean arterial pressure is effectively increased by intravenous infusions of norepineph-
rine at 0.1–1 μg/kg/min. According to the SOAP II study conducted using 1679 patients who 
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developed shock due to various etiologies, norepinephrine with a rate of 45.9% showed a 
50.2% lower mortality rate compared to dopamine in the total population and produced sig-
nificantly lower arrhythmia particularly atrial fibrillation (12.4 vs. 24.1%). Norepinephrine 
showed significantly better survival rates than dopamine treatment in the prospectively 
defined subgroup of CS patients [32].
4.3.2. Dobutamine
The inotropic dose range of dobutamine is between 2 and 20 μg/kg/min [33]. Based on the 
results of a multicenter cohort observational study on 1058 shock patients, following the 
German-Austrian guideline recommendations, the use of dopamine is an independent risk 
factor for mortality (p = 003), while this is not the case for dobutamine and norepinephrine 
[34]. Based on prospectively collected real-life data, epinephrine should be used only for 
resuscitation because it produces advanced organ damage and it is associated with higher 
mortality compared to dobutamine, levosimendan, and norepinephrine [35]. The European 
Association of Cardiology guidelines recommended the combination of levosimendan with 
a vasopressor agent in CSMI patients refractory to catecholamines or using it with a phos-
phodiesterase III inhibitor such as enoximone or milrinone, with or without dobutamine in 
intractable CS (ICS) patients [33]. The use of levosimendan or phosphodiesterase III inhibitors 
in shock patients who previously used chronic beta-blockers provides a better stabilization 
than dobutamine, and the results are similar to those with acute decompensated heart failure 
[36]. The German-Austrian CSMI guidelines recommend levosimendan, not PDE III inhibi-
tors [29]. More importantly, PDE III inhibitors are not recommended at all in STEMI patients 
according to the guidelines of the European Society of Cardiology (ESC) [37].
4.3.3. Phosphodiesterase III inhibitors
Enoximone (Perfan™) and milrinone are selective PDE III inhibitors that increase inotropy 
and decrease systemic vascular resistance. They do not cause changes in myocardial oxygen 
consumption.
At the same time, they can be combined with dobutamine, because their combined inotropic 
effect is greater than that of dobutamine and PDE III inhibitor alone [38]. When “bridge to 
transplantation” was evaluated according to a prospective randomized trial, it did not prove 
superior to dobutamine, and it also caused high treatment costs [27].
4.3.4. Levosimendan (Simdax™)
Levosimendan, which has been used for the treatment of decompensated heart failure, is a 
calcium-sensitizing drug with inotropic agents. It increases the myocardial contractility with 
vasodilatory properties; meanwhile, diastolic relaxation is not impaired. It increased the cardiac 
contractility mediated by calcium sensation of troponin C, vasodilation through the opening of 
potassium channels on the sarcolemma of smooth muscle cells in the vasculature, and cardio-
protection through the opening of mitochondrial potassium channels in the cardiomyocytes.
A single-center prospective randomized study comparing levosimendan and a PDE III inhibi-




was identified as the resolution of shock, but the study was prematurely terminated by the 
ethics committee due to the significant superiority of levosimendan in the transient analyses. 
Only 32 CSMI patients could be evaluated. The primary endpoint of 30-day survival was 
found to be significantly higher in the levosimendan group than in the enoximone group 
(69% 11/16 vs. 37%, 6/16) [38]. According to nonrandomized trials, levosimendan has positive 
effects such as increasing CO, LV stroke work index, and systemic vascular resistance [39, 40]. 
It has also been documented to improve right ventricular function by increasing the RV car-
diac power index (rVCPI) and decreasing pulmonary vascular resistance [39]. A small-scale 
study with 22 CSMI patients comparing levosimendan therapy with dobutamine treatment 
did not reveal any difference in 1-year mortality [41].
4.4. Percutaneous assist devices
Percutaneous circulatory support devices such as IABP, LV assist device (LVAD), or extracor-
poreal life support (ECLS) create treatment options for selected patients such as CS, cardio-
pulmonary resuscitation, or high-risk pPCI and CABG.
Percutaneous mechanical cardiac support (pMCS) devices, venoarterial extracorporeal mem-
brane oxygenation (VA-ECMO), and ECLS applications are quite appealing for patients 
with CSMI because these therapeutic approaches offer an option that can improve cardiac 
output by avoiding the cardiotoxic effects of catecholamine therapy. IABP as passive pMCS 
and many active pMCS and VA-ECMO/ECLS are used [42–46]. However, in a review of an 
IABP-SHOCK II trial conducted on 600 patients with CSMI, it was observed that no benefit 
was provided in postinfarction CS treated with IABP and without mechanical complications 
compared to conventional treatment. This condition was downgraded from Class I (level of 
evidence C) to Class IIIA in the European guidelines [5, 47]. The use of active pMCS and 
VA-ECMO, and the advantages that they can create, should be respected. However, there 
are no high-quality RCTs supporting the general use of active pMCS in patients with refrac-
tory CSMI [48, 49]. As a result, ESC guidelines do not suggest the routine use of IABP in CS 
[33, 37, 50, 51]. It can be used simultaneously in refractory CS for a short term as a bridge 
leading to the implantation of a durable left ventricular assist device depending on the age, 
comorbid factors, and neurological status of the patient [52]. ECLS/VA-ECMO may provide a 
respiratory support in patients with the coexistence of severe cardiac and pulmonary insuffi-
ciency. Although there are no randomized trials that can assess ECLS/VA-ECMO in CS, obser-
vational studies have shown that it is useful in CS occurring during acute and chronic heart 
failure and cardiac arrest patients [53, 54]. Current ESC guidelines for heart failure suggest the 
use of ECLS/VA-ECMO or other support devices for the treatment of acute heart failure until 
cardiac and organ functions are improved in CS.
Extracorporeal Life Support Organization (ELSO) 2017 suggested that the use of ECLS/
VA-ECMO should be considered when the mortality risk exceeds 50% despite optimal conven-
tional treatment in case of acute severe heart or pulmonary failure, whereas it was suggested 
as a primary indication when the rate exceeds 80%. The main goal of the ECLS/VA-ECMO is 
to provide rapid circulatory and respiratory stabilization until an adequate improvement in 
cardiac loading is obtained in refractory CS. Although there are no controlled randomized 
Advances in Extra-corporeal Perfusion Therapies18
trials on the efficacy of ECLS/VA-ECMO, it was established as an indication of Class IIb in 
European guidelines and indication of Class IIa in American guidelines after observational 
studies demonstrated its beneficial effects on survival compared to conventional treatment 
[51, 54, 55]. Early application of ECLS/VA-ECMO was recommended to prevent imminent 
multi-organ failure since it maximizes cardiac recovery potential [46]. The ECLS VA-ECMO 
is also used in postcardiotomy CS occurring in the range 0.2–6% after cardiac operation [56].
There is a relative contraindication in patients that have recovered from life-incompatible 
conditions, in situations where preexisting conditions adversely affect the quality of life (the 
state of the central nervous system, end-stage malignancy, high-risk systemic bleeding com-
plications), and in conditions that would not cause any benefit such as extreme old age or 
dependency; anatomical obstructions, if the treatment would take too long; or the existence 
of a fatal disease.
4.4.1. IABP
This has been the mainstay of mechanical CS treatment for a long period of time. IABP has 
become the most commonly used pMCS in the last decade. Some 10,000 IABPs were implanted 
in Germany alone in 2009 [57]. IABP, which is made of a polyurethane membrane mounted 
on a vascular 7.0–8.0 Fr catheter, is positioned in the descending thoracic aorta just distal to 
the left subclavian artery. This device matches its inflation and deflation times according to 
the cardiac cycle. The use of IABP improves coronary and peripheral circulation by increasing 
LV performance with diastolic balloon inflation and reduces afterload with systolic balloon 
deflation. IABP enables an increase in diastolic blood pressure and decrease in end-systolic 
pressure without affecting the mean blood pressure, cardiac output, cardiac power index, 
serum lactate levels, or by changing the doses of catecholamines. Accurate timing of inflation 
and deflation provides optimal support. Not all patients benefit from the support of IABP. It 
is a good prognostic indicator if it provides hemodynamic benefit [58]. If the procedure can be 
performed quickly, it should be applied as soon as possible before revascularization or trans-
fer and in the presence of experienced operators. In the large National Registry of Myocardial 
Infarction, the use of IABP was independently associated with survival at centers with higher 
rates of IABP use [59], whether or not PCI, fibrinolytic therapy, or no reperfusion was used 
[43]. Some of the many nonrandomized trials on the use of IABP in CSMI are positive, but 
those with neutral outcomes have also been seen [46]. Sjauw et al. summarized the available 
data in a systematic review and meta-analysis on IABP in STEMI patients with and without 
CS including nine cohorts of patients with CSMI (n = 10,259). The use of IABP in patients 
treated with thrombolysis showed a significant decrease in 30-day mortality by 18% when 
compared to unsupported needs of highly revascularization rates. In contrast, the use of IABP 
in patients treated with pPCI showed a significant increase in 30-day mortality by 6% [60].
A randomized IABP-SHOCK trial conducted with 45 PCMI-treated patients with CSMI 
proved that the simultaneous administration of IABP did not correct multi-organ dysfunc-
tion syndrome (MODS) and hemodynamics [61]. When an IABP-SHOCK II trial that had 
been performed afterward was examined, it was seen that the administration of IABP along 




12-month mortality [5, 47]. In a review made by the Cochrane group, the treatment of IABP 
was compared with the standard treatment (n = 384) and three LVAD treatments (n = 45) in 
four randomized clinical trials covering a total of 790 patients with CSMI in which the major-
ity of whom had been treated with the pPCI. No difference was noted in terms of 30-day 
mortality in the group treated with IABP compared to the group in which IABP was not used. 
It is thought that it can theoretically cause fewer complications and better support due to the 
improvement in the current technology coupled with improvements in automation, flexibility 
in treatment algorithms, and advances in placement speed and sheathless insertion thanks to 
its smaller catheter body, but there is no information to support these considerations.
IABP has rare but serious complications such as major bleeding, stroke, and local and sys-
temic infections. When compared with LVAD and ECLS, it has the lowest complication 
rate. Limb ischemia is the most commonly occurring vascular complication, but their rates 
have been reduced due to its small-diameter catheter and sheathless insertion. Aortic dis-
section, retroperitoneal hemorrhage, femoral hematomas, arteriovenous fistulas, and femo-
ral pseudoaneurysms, which may be seen in any femoral artery procedure, may also occur 
in IABP. Ischemia and necrosis in certain areas may occur with the embolization of aortic 
atherosclerotic components to the peripheral vascular bed. Visceral organs may be affected 
adversely as a result of inappropriate balloon catheter diameter and placement. In contrast to 
all of these clinical observations, randomized IABP-SHOCK II trial revealed that high compli-
cation rates secondary to IABP were not observed in patients treated with IABP.
4.4.2. LVADs
LV assist devices (LVADs) are theoretically appealing since they break the vicious ischemia 
cycle by providing temporary circulatory support, breaking hypotension and myocardial 
dysfunction, enabling recovery from the stunned and hibernating myocardium, and allowing 
the reversal of neurohumoral change. Active pMCS is hemodynamically more potent than 
IABP [42, 43, 46, 48]. However, device-related complications and permanent organ damage 
are the most important limiting factors. LVADs support the return of the oxygenated blood 
drained from the left side of the heart into the systemic arteries with pulsed circulation or 
continuous flow by circulating it through a device. Surgically implanted LVADs pump the 
blood taken from the apex of the left ventricle via a cannula.
4.4.2.1. The TandemHeart (CardiacAssist Inc., Pittsburgh, PA)
The TandemHeart is a left atrial-to-femoral arterial LVAD device. It drains the blood through 
a cannula placed in the left atrium entering from the femoral vein transseptally. The blood 
returns to a systemic artery, the femoral artery, and perfuses into the thoracic and abdominal 
aorta in a retrograde manner. The system is capable of delivering flow up to 4.0 L/min at 
7500 rpm. The patients with CSMI treated with TandemHeart and Impella® family placed by 
passing through the aortic valve and pPCI were evaluated in small randomized clinical trials 
[48]. In the meta-analysis of four trials randomizing 148 patients treated with TandemHeart, 
Impella®, or Impella CP®, the results were compared with the patient group treated with 
IABP [48, 62–65]. Although hemodynamics were better in patients treated with pMCS, no 
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significant difference was detected in terms of mortality, but complications such as bleeding 
and leg ischemia were higher in that group.
4.4.2.2. The Impella® (Abiomed)
The Impella® pump is a nonpulsatile axial flow pump consisting of a suction cannula with a 
turbine positioned in the LV in order to push the blood into the ascending aorta. It has three 
versions 2.5, 5, and CP. Impella® is inserted through the femoral artery by 2.5 and CP standard 
catheterization procedures into the ascending aorta and then placed in the left ventricle by 
passing it through the aortic valve. The inlet area, located at the distal tip of the cannula, has 
four openings that allow the blood to be drained into the inlet and channeled through the 
cannula. The placement of Impella 5.0® is the same except that it requires surgical cutdown. 
The axial flow pump system reduces the left ventricular load and causes a reduction in the 
LV wall stress.
The Impella 2.5®, Impella CP®, Impella 5.0®, and Impella LD® catheters, in conjunction with 
the Automated Impella® Controller (collectively, “Impella® System Therapy”), are temporary 
ventricular support devices intended for short-term use (≤4 days for the Impella 2.5® and 
Impella CP® and ≤6 days for the Impella 5.0® and Impella LD®) and indicated for the treatment 
of ongoing cardiogenic shock that occurs immediately (<48 h) following acute myocardial 
infarction or open heart surgery or in the setting of cardiomyopathy, including peripartum 
cardiomyopathy, or myocarditis as a result of isolated left ventricular failure that is not 
responsive to optimal medical management and conventional treatment measures (includ-
ing volume loading and use of pressors and inotropes, with or without IABP). The intent of 
Impella® System Therapy is to reduce ventricular work and to provide the circulatory sup-
port necessary to allow heart recovery and early assessment of residual myocardial function 
(http://www.abiomed.com/impella/impella-25) (Figure 1).
4.4.2.3. HeartMate PHP (Thoratec Corporation)
This axial device system is composed of a percutaneously inserted, Nitinol-covered cannula 
through the femoral artery, integrated with a tribune (impeller) having a diameter of 13 Fr. 
Its major design feature is a collapsible elastomeric impeller and Nitinol cannula giving this 
device the lowest profile insertion cannula with the highest flow. When it is placed by passing 
through the aortic valve once, it may create a continuous flow of more than 4 L/min at reason-
able operating speeds, resulting in reduced LV end-diastolic pressure and volume. When it 
has to be replaced again, the system collapsed by 13 Fr. The information is limited to a small 
registry trial made up of 46 patients, and the results of which have not been published yet.
4.4.2.4. The iVAC 2L (Terumo Interventional Systems)
The iVAC 2L system is introduced percutaneously through the femoral artery and can pro-
vide a pulsatile support of approximately 2 L/min using an extracorporeal membrane pump 
via a 17 Fr cannula. In the systolic phase of the heart, the blood is aspirated from the LV 




ejects the blood back through the catheter, then reopens the catheter valve, and delivers the 
blood to the ascending aorta through the side outflow port, thereby creating an “extra heart 
beat.” Data are limited to a small case series, and the clinical impact of this device needs to be 
investigated further (Figure 2).
4.4.3. VA-ECMO
Advances made since the introduction of the first cardiopulmonary bypass system in 1953 
have enabled the development of percutaneous devices. In fact, today’s VA-ECLS devices con-
sist of venous and arterial cannulas, tubing, a membrane oxygenator with gas blender, a con-
tinuous flow centrifugal pump, and a heat exchanger compensating for heat loss originating 
from extracorporeal circulation. Generally, a 16–19 Fr arterial cannula is placed in the ascend-
ing aorta, and an 18–21 Fr venous cannula is placed in the right atrium. The blood drained 
from the right atrium is pumped into the heat exchanger and membrane oxygenator and 
eventually returns to the femoral artery. The blood is drained from the main points separated 
from cardiopulmonary bypass (CPB) devices into an open reservoir passively, whereas there 
is a closed circuit in the VA-ECLS devices, and negative pressure is applied for venous blood 
Figure 1. Installation of Impella®.
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return [66]. The pump continues to provide pulsatile arterial blood pressure with the continu-
ous flow until the circulation is fully supported by a cardiopulmonary bypass device. ECLS is 
used in LV, RV, and biventricular insufficiency with the flow exceeding 5 L/min.
Venoarterial extracorporeal oxygenation or its synonym extracorporeal life support (ECLS) and 
LVAD were commonly used as a bridge for heart transplantation in CS patients [67]. ECLS takes 
the blood circulation out of the body into a membrane oxygenator and takes some of the work-
load of the right and left heart and lungs. While anticoagulation is required for ECLS and per-
cutaneous LVAD, it may be optional for surgically implanted LVADs. In reports concerning the 
large LVAD series, 74% of 49 surviving patients underwent transplantation, and 87% of the trans-
plant patients in whom LVAD was placed surgically also survived and were discharged [68, 51]. 
Although early LVAD and extracorporeal life support and subsequently transplantation have 
been recommended as an alternative approach to emergency revascularization, these non-sys-
tematic direct comparative and observational studies have yielded contradictory results. In a 
study conducted with surgical LVAD with and without CABG, the mortality was found to be 
higher in patients with CABG in whom LVAD was inserted in the early period after MI [69].
While VA-ECMO may support pulmonary functions along with cardiac functions, they also 
have the advantage of being implanted in distant centers [46, 70]. After the publication of the 
neutral results of the IABP-SHOCK trial, the number of VA-ECMO applications increased 
dramatically [57]. The application number was 500 in Germany in 2012 increasing to 3000 in 
2014 [57]. This worrisome increase in the use of VA-ECMO in CSMI patients is a very serious 
issue that needs to be assessed in more detail since it does not rely on concrete evidence but 
rather on conventional wisdom based on pathophysiology and the positive results published 
in observational studies [49, 71]. An increase of 3–6 L/min in the flow, which is provided 
by VA-ECMO and which is necessary, cannot ensure the survival of CSMI patients. There 
are drawbacks involved in using these devices as a result of the high rates of complications 
such as the large cannula sizes, major bleeding, lower extremity ischemia, compartment syn-
drome, amputation, stroke, severe infections, difficult weaning, lack of direct left ventricu-
lar  unloading, and increase in afterload [72, 73]. Attempts to counteract the problem of left 




 ventricular loading and increase in afterload with VA-ECMO are being made with the combi-
nation of an unloading device such as IABP or the use of Impella® [74, 75]. Better weaning and 
lower in-hospital and 28-day mortality were reported with Impella® of VA-ECMO along with 
IABP in a propensity-matched national registry [74]. Considering the lack of RCTs, systematic 
reviews should be taken into account as well as two small nonrandomized registries (n = 95) 
comparing VA-ECMO with IABP and Impella® and two other studies (n = 140) conducted with 
Impella RD® and TandemHeart [54, 75]. Considering the 30-day survival rate of VA-ECMO, 
in this meta-analysis, it is obviously superior to IABP with 33% absolute survival rate. No 
benefit was observed when compared with ECLS and pMCS (Impella®, TandemHeart). In 
conclusion, the total meta-analysis did not indicate any significant benefits. When addressed 
as a whole, the meta-analysis data of VA-ECMOs/ECLS and pMCS are inconsistent: on the 
one hand, pMCSs are not better than IABP, whereas, on the other, VA-ECMOs/ECLS are bet-
ter than IABP while they are not better than pMCSs. Of course, there is a need for higher-
quality RCTs to be able to answer the questions about the routine use of VA-ECMO/ECLS 
in treatment-resistant CS patients [44, 49]. It is seen that 75% of the survivors after ECLS are 
able to go about their daily life, 25% of them return to work or school, and 57% of them are 
not limited in their usual activities. However, when compared to a normative age-matched 
population, significantly lower quality-of-life indices are reported [76].
4.5. Reperfusion
Coronary revascularization probably with pPCI should be planned as soon as possible in 
STEMI/NSTEMI patients with impaired pump function. In the IABP-SHOCK II trial conducted 
with 600 patients between 2009 and 2012, emergency coronary revascularizations were per-
formed with pPCI in 95.8% of them and with CABG in 3.5% usually after unsuccessful pPCI, 
and revascularization was not performed only in 3.2% of them [5]. Early coronary revascular-
ization is the key recommendation for treatment of CSMI patients [29, 32, 33, 37, 50, 51]. The 
SHOCK trial conducted with 302 CSMI patients between 1993 and 1998 revealed a tendency 
for early revascularization compared to conservative treatment whether with pPCI (64%) or 
CABG (36%) in terms of 30-day mortality (56.0 vs. 47.6%; p = 0.11) [77]. However, the 6-month 
(49.7 vs. 36.9%; p = 0.027), 12-month (46.7 vs. 33.6%; p < 0.04), and even 6-year (32.8 vs. 19.6%; 
p = 0.03) survival rates, for early revascularization, are significantly high [77–79]. SMASH (Swiss 
Multicenter Trial of Angioplasty for SHOCK) trial, which is the second study suitable for early 
coronary revascularization, was prematurely terminated due to low participation after only 55 
CSMI patients were included. This study seemed neutral regarding 30-day mortality [5]. The 
low mortality rates of CSMI patients in the data registry reports of numerous countries such as 
France, Italy, Switzerland, Sweden, and the United States in the past 30 years were attributed 
to the increased rates of pPCI [3]. The “real-world” situation in Germany is reflected by the 
registry data addressing 2.818 CSMI-treated patients, of whom 85% were treated with pPCI, 
4.2% with CABG, and 8.9% with noninterventional treatment. Hospital mortality rates were 
42% for pPCI, 21.7% for CABG, and 47.8% for noninterventional treatment [80].
4.5.1. Types of revascularization
The preferred approach is primary percutaneous coronary intervention (pPCI). The decision 
to carry out revascularization in CSMI patients with multivessel disease or left main coronary 
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artery should be made depending on the patient’s medical information, coronary anatomy, 
procedural risks, potential delays in treatment, and patient preferences in cooperation with 
a “heart team” composed of cardiologists and surgeons [32, 81, 82]. Registry data indicated 
similar mortality rates between pPCI and CABG, while they sometimes suggested that CABG 
was better [80, 81]. Chest pain units and shock centers in the network generated for MI patients 
should allow to rapid transfer of CSMI patients to those centers where cardiac catheterization 
and pPCI are performed [33, 37, 83]. Only in cases in which emergency cardiac catheterization 
cannot be performed in a reasonable time period, systemic fibrinolysis should be preferred 
as the second best option, and cardiac catheterization should be performed because systemic 
fibrinolysis is not as effective as catheter revascularization [84].
The standard concept for pPCI in CSMI patients is reopening only the culprit coronary lesion. 
Even though 70–80% of CSMI patients in fact have multivessel disease, the mortality rate of 
opening multiple vessels in the same session is high. According to the registry data of the 
IABP-SHOCKII trial, a significant difference could not be demonstrated between multives-
sel pPCI and the culprit lesion only pPCI in terms of 12-month mortality [85]. The European 
Society of Cardiology guidelines recommend the implantation of a drug-eluting stent (DES) 
over bare metal stents (BMS) in patients with STEMI and also in NSTEMI patients with acute 
coronary syndrome [29, 37]. However, the roles of DES and BMS are still indefinite. All the 
long-term causes of mortality were better in those who underwent DES implantation, while the 
other two were neutral in a retrospective analysis [86, 87]. Still, even though using DES instead 
of BMS does not have any adverse effect, the use of DES is still recommended in CSMI patients.
5. Conclusion
Examining the patients with CS, we can see that we have many problems to deal with and 
solve. Due to ever-increasing risk factors for MI, particularly due to rapidly increasing world 
population, aging populations, and tobacco use, the number of CS patients is increasing day 
by day despite the serious advances and solutions in ACS. Although pMCS devices manufac-
tured specifically with advancing technology are considered to be good solutions, they do pose 
new and serious problems. They are not suitable for every country or society due to their high 
application and device costs and particularly due to the fact that they cannot guarantee life. We 
need to allocate more resources to the abovementioned problems for the sake of public health 
through the world, and we need to produce pMCS devices that are suitable for each population, 
easy to apply, inexpensive, transportable, permanent, and effective so that the patient can be 
transferred to a cardiac center no matter where the patient is. One clear fact revealed by this 
study is the lack of clarity with respect to pMCS indications due to a low number of controlled 
randomized clinical trials. Early and effective revascularization is the best treatment option for 
CS. To this end, those organizations operating on both national and global bases are going to 
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